Atherectomy products, chronic total occlusion devices, balloon catheters, and embolic protection devices accounted for $836 million in U.S. sales during 2013. As discussed in Life Science Intelligence's new report, strong growth is expected in the U.S. market in coming years due to clinical efforts to improve the effectiveness of interventional methods for treating peripheral artery disease (PAD); attempts to refine techniques; and the impact of new products such as drug-coated balloons (DCBs), the first of which became commercially available in October 2014. This report examines the forces affecting the U.S. market for these technologies from 2012-2019 and covers key issues, such as:
• Quantitative factors including units, pricing, and product sales;
• The timing and market introduction of important new technologies;
• Procedure volumes as well as other key infrastructure and market metrics; and
• The competitive landscape.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
